CD38 and plasma cell myeloma: If we rely primarily on CDC, ADCP, or ADCC for control of myeloma it makes sense to introduce a treatment-free interval, which will allow re-expression of CD38 by the myeloma cells and subsequently, introduce a re-treatment approach where daratumumab is used again in an appropriate new combination.